BidaskClub upgraded shares of Shire (NASDAQ:SHPG) from a sell rating to a hold rating in a report published on Thursday.

A number of other equities analysts have also recently commented on SHPG. Berenberg Bank cut shares of Shire from a buy rating to a hold rating in a research note on Friday, September 7th. ValuEngine cut shares of Shire from a hold rating to a sell rating in a research note on Thursday, September 6th. Cantor Fitzgerald set a $222.00 price target on shares of Shire and gave the stock a buy rating in a research note on Tuesday, July 31st. Evercore ISI cut shares of Shire from an outperform rating to a market perform rating and set a $196.00 price target for the company. in a research note on Tuesday, September 4th. Finally, Sanford C. Bernstein cut shares of Shire from an outperform rating to a market perform rating in a research note on Tuesday, September 4th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $200.75.

SHPG stock opened at $177.30 on Thursday. Shire has a 12 month low of $123.73 and a 12 month high of $177.75. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.55 and a quick ratio of 1.02. The stock has a market cap of $52.51 billion, a P/E ratio of 11.70, a PEG ratio of 1.53 and a beta of 1.22.

Shire (NASDAQ:SHPG) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $3.88 EPS for the quarter, topping analysts’ consensus estimates of $3.67 by $0.21. Shire had a net margin of 31.06% and a return on equity of 13.22%. The firm had revenue of $3.92 billion during the quarter. During the same period in the prior year, the firm posted $3.73 earnings per share. Shire’s revenue for the quarter was up 4.6% on a year-over-year basis. research analysts expect that Shire will post 15.27 earnings per share for the current year.

The business also recently disclosed a dividend, which will be paid on Friday, October 19th. Shareholders of record on Friday, September 7th will be given a $0.168 dividend. The ex-dividend date is Thursday, September 6th. Shire’s dividend payout ratio (DPR) is 2.24%.

A number of institutional investors have recently added to or reduced their stakes in SHPG. Rockefeller Capital Management L.P. purchased a new stake in Shire in the 1st quarter valued at about $113,097,000. PointState Capital LP boosted its position in Shire by 4,642.0% in the 2nd quarter. PointState Capital LP now owns 711,296 shares of the biopharmaceutical company’s stock valued at $120,067,000 after buying an additional 696,296 shares during the period. LMR Partners LLP purchased a new stake in Shire in the 2nd quarter valued at about $55,664,000. SG Americas Securities LLC boosted its position in Shire by 1,634.4% in the 2nd quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock valued at $32,671,000 after buying an additional 182,388 shares during the period. Finally, Prosight Management LP purchased a new stake in Shire in the 1st quarter valued at about $21,828,000. 17.86% of the stock is owned by institutional investors.

About Shire

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.